- Stocks
- Healthcare
- NASDAQ: HCWB

Price (delayed)

$0.629

Market cap

$23.79M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.76

Enterprise value

$27.98M

HCWB's revenue has surged by 107% since the previous quarter and by 44% year-on-year

HCW Biologics's gross profit has soared by 107% from the previous quarter and by 44% YoY

HCW Biologics's quick ratio has shrunk by 94% YoY and by 34% QoQ

HCW Biologics's equity has plunged by 73% YoY and by 35% from the previous quarter

What are the main financial stats of HCWB

Market
Valuations
Earnings

Shares outstanding

37.82M

Market cap

$23.79M

Enterprise value

$27.98M

Price to earnings (P/E)

N/A

Price to book (P/B)

2.59

Price to sales (P/S)

20.14

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

24.07

Revenue

$1.16M

EBIT

-$27.2M

EBITDA

-$26.12M

Free cash flow

-$28.51M

Per share
Balance sheet
Liquidity

EPS

-$0.76

Free cash flow per share

-$0.77

Book value per share

$0.24

Revenue per share

$0.03

TBVPS

$0.82

Total assets

$30.43M

Total liabilities

$21.69M

Debt

$8.27M

Equity

$8.74M

Working capital

-$7.2M

Debt to equity

0.95

Current ratio

0.46

Quick ratio

0.39

Net debt/EBITDA

-0.16

Margins
Efficiency
Dividend

EBITDA margin

-2,246.9%

Gross margin

100%

Net margin

-2,356.1%

Operating margin

-2,395.6%

Return on assets

-81.7%

Return on equity

-146.8%

Return on invested capital

-105.8%

Return on capital employed

-159.9%

Return on sales

-2,339.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the HCW Biologics stock price performed over time

Intraday

6.61%

1 week

-8.84%

1 month

-12.64%

1 year

-71.15%

YTD

-48.65%

QTD

-3.23%

How have HCW Biologics's revenue and profit performed over time

Revenue

$1.16M

Gross profit

$1.16M

Operating income

-$27.85M

Net income

-$27.39M

Gross margin

100%

Net margin

-2,356.1%

HCWB's revenue has surged by 107% since the previous quarter and by 44% year-on-year

HCW Biologics's gross profit has soared by 107% from the previous quarter and by 44% YoY

The net income has dropped by 53% year-on-year and by 10% since the previous quarter

The operating income has dropped by 50% year-on-year and by 8% since the previous quarter

What is HCW Biologics's growth rate over time

What is HCW Biologics stock price valuation

P/E

N/A

P/B

2.59

P/S

20.14

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

24.07

HCWB's EPS is down by 49% year-on-year and by 9% since the previous quarter

HCW Biologics's equity has plunged by 73% YoY and by 35% from the previous quarter

The P/B is 38% lower than the last 4 quarters average of 4.0

HCWB's revenue has surged by 107% since the previous quarter and by 44% year-on-year

HCWB's price to sales (P/S) is 78% less than its last 4 quarters average of 88.8

How efficient is HCW Biologics business performance

The ROA has shrunk by 116% YoY and by 20% QoQ

HCWB's return on invested capital has dropped by 72% year-on-year and by 16% since the previous quarter

HCWB's ROS is up by 47% since the previous quarter but it is down by 7% year-on-year

The ROE is down by 45% since the previous quarter

What is HCWB's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for HCWB.

How did HCW Biologics financials performed over time

HCWB's total assets is 40% greater than its total liabilities

HCWB's total liabilities has soared by 99% YoY and by 44% from the previous quarter

HCW Biologics's quick ratio has shrunk by 94% YoY and by 34% QoQ

The company's debt is 5% lower than its equity

HCW Biologics's debt to equity has surged by 102% QoQ

HCW Biologics's equity has plunged by 73% YoY and by 35% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.